MPO and prostate cancer: Remarkably, metformin reduced neutrophil accumulation in the surrounding tissue, as demonstrated in a previous study, suggesting its capacity to reduce oxidative stress, myeloperoxidase activity, and tissue damage in animal models of diabetes and prostate cancer [38].